Monday, August 23, 2021

Cocrystal Pharma Inc. (COCP)
2Q21 Reported With Clinical Milestones For 2021-22

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cocrystal Reports 2Q21 With Clinical Trial Milestones. Cocrystal Pharmaceuticals reported 2Q21 results of a loss of $3.8 million or $(0.04) per share, compared with our expected loss of $3.1 million or (0.04) per share. Differences from our estimates were largely due to higher Research expenses for product development and lower General Expenses. The company ended the quarter with $67.1 million in cash. Based on our estimates for research programs and net losses, we expect this cash to last into 2024.

COVID-19 Program Has Two Preclinical Studies.   Cocrystal has two programs developing protease inhibitors against the virus that causes COVID-19, SARS-CoV-2.  The company plans to hold a pre-IND meeting with the FDA for CDI-45205 later this year, with an IND enabling study in 1H22 using intranasal/pulmonary delivery. A pre-IND for an oral inhibitor in is expected in 1H22, followed by an IND-enabling ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.